HUTCHMED DRC (HCM)
[Press Release] HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for Gastric Cancer with MET Amplification
[Press Release] HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for Gastric Cancer with MET Amplification
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General